The STAR of the DLC family

References

• Bishop A, Hall A. RhoGTPases and their effector proteins. Biochem J 2000;348:241–55
   PubMed Web of Science ®Google Scholar
• Hall A, Nobes C. RhoGTPases: molecular switches that control the organization and dynamics of the actin cytoskeleton. Phil Trans R Soc Lond 2000;355:965–70
   PubMed Web of Science ®Google Scholar
• Hwang SL, Hong YR, Sy WD, et al. Rac1 gene mutations in human brain tumours. Eur J Surg Oncol 2004;30:68–72
   Google Scholar
• Johnson DI. Cdc42: an essential Rho-type GTPase controlling eukaryotic cell polarity. Microbiol Mol Biol Rev 1999;63:54–105
   PubMed Web of Science ®Google Scholar
• Burbelo PD, Drechsel D, Hall A. A conserved binding motif defines numerous candidate target proteins for both Cdc42 and Rac GTPases. J Biol Chem 1995;270:29071–4
   PubMed Web of Science ®Google Scholar
• Adamson P, Paterson HF, Hall A. Intracellular localization of the P21rho proteins. J Cell Biol 1992;119:617–27
   PubMed Web of Science ®Google Scholar
• Karlsson R, Pedersen ED, Wang Z, et al. RhoGTPase function in tumorigenesis. Biochim Biophys Acta 2009;1796:91–8
   PubMed Web of Science ®Google Scholar
• Abecassis I, Olofsson B, Schmid M, et al. RhoA induces MMP-9 expression at CD44 lamellipodial focal complexes and promotes HMEC-1 cell invasion. Exp Cell Res 2003;291:363–6
   PubMed Web of Science ®Google Scholar
• Raftopoulou M, Hall A. Cell migration: RhoGTPases lead the way. Dev Biol 2004;265:23–32
   PubMed Web of Science ®Google Scholar
• DerMardirossian C, Bokoch G. GDIs: central regulatory molecules in RhoGTPase activation. Trends Cell Biol 2005;15:356–63
   PubMed Web of Science ®Google Scholar
• Lin M, van Golen K. Rho-regulatory proteins in breast cancer cell motility and invasion. Breast Cancer Res Treatment 2004;84:49–60
   PubMedGoogle Scholar
• Rittinger K, Walker PA, Eccleston JF, et al. Crystal structure of a small G protein in complex with the GTPase-activating protein rhoGAP. Nature 1997;388:693–7
   PubMed Web of Science ®Google Scholar
• Yau TO, Leung TH, Lam S, et al. Deleted in liver cancer 2 (DLC2) was dispensable for development and its deficiency did not aggravate hepatocarcinogenesis. PLoS One 2009;4:e6566
   Google Scholar
• Ahmadian MR, Wiesmuller L, Lautwein A, et al. Structural differences in the minimal catalytic domains of the GTPase-activating proteins p120GAP and neurofibromin. J Biol Chem 1996;271:16409–15
   PubMed Web of Science ®Google Scholar
• Moon SY, Zheng Y. RhoGTPase-activating proteins in cell regulation. Trends Cell Biol 2003;13:13–22
   PubMed Web of Science ®Google Scholar
• Gamblin SJ, Smerdon SJ. GTPase-activating proteins and their complexes. Curr Opin Struct Biol 1998;8:195–201
   PubMed Web of Science ®Google Scholar
• Moskwa P, Paclet MH, Dagher MC, et al. Autoinhibition of p50 RhoGTPase-activating protein (GAP) is released by prenylated small GTPases. J Biol Chem 2009;280:6716–20
   Google Scholar
• Lamarche N, Hall A. GAPs for rho-related GTPases. Trends Genet 1994;10:436–40
   PubMed Web of Science ®Google Scholar
• Kandpal RP. RhoGTPase activating proteins in cancer phenotypes. Curr Protein Pept Sci 2006;7:355–65
   PubMedGoogle Scholar
• Bernards A, Settleman J. GAP control: regulating the regulators of small GTPases. Trends Cell Biol 2004;14:377–85
   PubMed Web of Science ®Google Scholar
• Tcherkezian J, Lamarche-Vane N. Current knowledge of the large RhoGAP family of proteins. Biol Cell 2007;99:67–86
   PubMed Web of Science ®Google Scholar
• Kim TY, Vigil D, Der CJ, et al. Role of DLC-1, a tumor suppressor protein with RhoGAP activity, in regulation of the cytoskeleton and cell motility. Cancer Metastasis Rev 2009;28:77–83
   PubMedGoogle Scholar
• Qian X, Li G, Asmussen HK, et al. Oncogenic inhibition by a deleted in liver cancer gene requires cooperation between tensin binding and Rho-specific GTPase-activating protein activities. Proc Natl Acad Sci USA 2007;104:9012–17
   PubMedGoogle Scholar
• Li H, Fung KL, Jin DY, et al. Solution structures, dynamics, and lipid-binding of the sterile alpha-motif domain of the deleted in liver cancer 2. Proteins 2007;67:1154–66
   Google Scholar
• Liao YC, Lo SH. Deleted in liver cancer-1 (DLC-1): a tumor suppressor not just for liver. Int J Biochem Cell Biol 2008;40:843–7
   PubMed Web of Science ®Google Scholar
• Kwan JJ, Donaldson LW. The NMR structure of the murine DLC2 SAM domain reveals a variant fold that is similar to a four-helix bundle. BMC Struct Biol 2007;7:34
   Google Scholar
• Grise F, Bidaud A, Moreau V. RhoGTPases in hepatocellular carcinoma. Biochim Biophys Acta 2009;1795:137–51
   PubMedGoogle Scholar
• Plaumann M, Seitz S, Frege R, et al. Analysis of DLC-1 expression in human breast cancer. J Cancer Res Clin Oncol 2003;129:349–54
   Google Scholar
• Goodison S, Yuan J, Sloan D, et al. The RhoGAP protein DLC-1 functions as a metastasis suppressor in breast cancer cells. Cancer Res 2005;65:6042–53
   PubMed Web of Science ®Google Scholar
• Wong CM, Yam J, Ching YP, et al. RhoGTPase-activating protein deleted in liver cancer suppresses cell proliferation and invasion in hepatocellular carcinoma. Cancer Res 2005;65:8861–8
   PubMedGoogle Scholar
• Durkin M, Yuan BZ, Zhou X, et al. DLC-1: a RhoGTPase-activating protein and tumor suppressor. J Cell Mol Med 2007;11:1185–207
   PubMed Web of Science ®Google Scholar
• Durkin ME, Ullmannova V, Guan M, et al. Deleted in liver cancer 3 (DLC-3), a novel RhoGTPase-activating protein, is downregulated in cancer and inhibits tumor cell growth. Oncogene 2007;26:4580–9
   Google Scholar
• Salhia B, Tran NL, Chan A, et al. The guanine nucleotide exchange factors trio, Ect2, and Vav3 mediate the invasive behavior of glioblastoma. Am J Pathol 2008;173:1828–38
   PubMed Web of Science ®Google Scholar
• Kawai K, Kiyota M, Seike J, et al. START-GAP3/DLC3 is a GAP for RhoA and Cdc42 and is localized in focal adhesions regulating cell morphology. Biochem Biophys Res Commun 2007;364:783–9
   Google Scholar
• Ching YP, Wong CM, Chan SF, et al. Deleted in liver cancer (DLC) 2 encodes a RhoGAP protein with growth suppressor function and is underexpressed in hepatocellular carcinoma. J Biol Chem 2003;278:10824–30
   Google Scholar
• Ng DC, Chan SF, Kok KH, et al. Mitochondrial targeting of growth suppressor protein DLC2 through the START domain. FEBS Lett 2006;580:191–8
   Google Scholar
• Ullmannova V, Popescu NC. Expression profile of the tumor suppressor genes DLC-1 and DLC-2 in solid tumors. Int J Oncol 2006;29:1127–32
   PubMed Web of Science ®Google Scholar
• Leung TH, Ching YP, Yam JW, et al. Deleted in liver cancer 2 (DLC2) suppresses cell transformation by means of inhibition of RhoA activity. Proc Natl Acad Sci USA 2005;102:15207–12
   Google Scholar
• Kawai K, Seike J, Iino T, et al. START-GAP2/DLC2 is localized in focal adhesions via its N-terminal region. Biochem Biophys Res Commun 2009;380:736–41
   Google Scholar
• Xiaorong L, Wei W, Liyuan Q, et al. Underexpression of deleted in liver cancer 2 (DLC2) is associated with overexpression of RhoA and poor prognosis in hepatocellular carcinoma. BMC Cancer 2008;8:205
   Google Scholar
• de Tayrac M, Etcheverry A, Aubry M, et al. Integrative genome-wide analysis reveals a robust genomic glioblastoma signature associated with copy number driving changes in gene expression. Genes Chromosomes Cancer 2009;48:55–68
   PubMed Web of Science ®Google Scholar
• Leung TH, Yam JW, Chan LK, et al. Deleted in liver cancer 2 suppresses cell growth via the regulation of the Raf-1–ERK1/2–p70S6K signalling pathway. Liver Int 2010;30:1315–23
   Google Scholar